Literature DB >> 2292526

Pharmacokinetics of cefpodoxime in young and elderly volunteers after single doses.

D Tremblay1, A Dupront, C Ho, D Coussediere, B Lenfant.   

Abstract

Three pharmacokinetic studies involving single oral doses of cefpodoxime proxetil in healthy volunteers are reported. The first study was to determine the absolute bioavailability of cefpodoxime, the second was to study the relationship between the oral dose of cefpodoxime proxetil and pharmacokinetic parameters of cefpodoxime, and the third was to compare the pharmacokinetics of cefpodoxime in healthy young and elderly volunteers. Half the dose of cefpodoxime orally administered as cefpodoxime proxetil in tablet form reaches the systemic circulation, while 80% of the cefpodoxime absorbed is excreted unchanged in urine. The volume of distribution is large (32.3 l). The pharmacokinetics of cefpodoxime were linear in young and elderly subjects after 100 and 200 mg oral doses, which are those used therapeutically. The Cmax was about 1.4 mg/l (after 100 mg) and 2.6 mg/l (after 200 mg). Deviation from linearity appeared at 400 mg and the effect was confirmed at 800 mg. The differences between young and elderly subjects were negligible, with the exception of the half-life which increased by only 14%, from 2.67 to 3 h. Dosage adjustment is therefore not necessary in the elderly.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2292526     DOI: 10.1093/jac/26.suppl_e.21

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  17 in total

1.  Detection of favorable oral cephalosporin-clavulanate interactions by in vitro disk approximation susceptibility testing of extended-spectrum-Beta-lactamase-producing members of the enterobacteriaceae.

Authors:  Jennifer D Campbell; James S Lewis; M Leticia McElmeel; Letitia C Fulcher; James H Jorgensen
Journal:  J Clin Microbiol       Date:  2011-12-14       Impact factor: 5.948

2.  Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function.

Authors:  J V St Peter; M T Borin; G S Hughes; J S Kelloway; B E Shapiro; C E Halstenson
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

Review 3.  Comparative pharmacokinetics of the new oral cephalosporins.

Authors:  H Lode; M Fassbender; T Schaberg; K Borner; P Koeppe
Journal:  Drugs       Date:  1994       Impact factor: 9.546

4.  Effect of food on absorption of cefpodoxime proxetil oral suspension in adults.

Authors:  M T Borin; K K Forbes
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 5.  A review of the pharmacokinetics of cefpodoxime proxetil.

Authors:  M T Borin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 6.  Cefpodoxime proxetil in upper respiratory tract infections.

Authors:  E Bergogne-Berezin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

7.  Effects of nifedipine and diltiazem on pharmacokinetics of cefpodoxime following its oral administration.

Authors:  A Deslandes; F Camus; C Lacroix; C Carbon; R Farinotti
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

8.  Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.

Authors:  C A Johnson; A Ateshkadi; S W Zimmerman; G S Hughes; W A Craig; P M Carey; M T Borin
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 9.  Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1993-04       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of newer cephalosporins.

Authors:  M E Klepser; M N Marangos; K B Patel; D P Nicolau; R Quintiliani; C H Nightingale
Journal:  Clin Pharmacokinet       Date:  1995-05       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.